Immutep, Eddingpharm In ImmuFact Development Pact

Immutep S.A. and Eddingpharm have entered an agreement for the development, commercialization, and manufacture of Immutep’s ImmuFact IMP321 in China. The companies plan to develop the product for first-line metastatic breast cancer, as well as other first-line metastatic indications. Financial details were undisclosed but include milestone payments and royalties. Burrill Securities acted as financial advisor for the transaction.
 
The agreement grants Eddingpharm exclusive rights to develop and market IMP321 in mainland China, Hong Kong, Macau and Taiwan. Immutep will provide full technical support for the development of the product.  
 
“We have been very impressed by the dynamic and innovative approach of Eddingpharm, and believe them to have the capability of driving the development of IMP321 in China,” said John Hawken, chief executive officer. “Immutep is continuing the development of IMP321 in Europe and the USA. We are in partnering discussions at present.”
 
“We are excited to be entering the new field of immuno-oncology. We believe that immuno-oncology will revolutionize cancer treatment,” said Xin Ni, chairman and chief executive officer of Eddingpharm. “Our priority is bringing new and effective treatments to patients. We look forward to working closely with Immutep to develop IMP321 in first-line metastatic breast cancer as well as other first-line metastatic indications.”